#volitionrx
Text
Volitionrx Limited Reports Significant Loss Despite Revenue Increase
Volitionrx Limitedns recent financial results give cause for concern and indicate a bearish outlook for the company. Despite reporting a strong revenue increase of 103.795% year-on-year, reaching $0.24 million, the company still suffered a significant loss of $-0.12. This suggests that the companyns expenses may be outpacing its revenue growth, raising doubts about its ability to achieve profitability.Comparing Volitionrxns revenue advancement in the fourth quarter of 2023 with its industry peers in the In Vitro and In Vivo Diagnostic Substances sector, the company fared well, with a 14.53% business advance. However, it should be noted that this quarterns revenue growth performance was substantially higher than the average achieved during the same period in the previous year, which saw a deficit of $-0.11 per share and a revenue surge of 47.674% from $0.17 million. This indicates a potential slowing of revenue growth, as the percentage increase is lower in comparison.Furthermore, Volit https://csimarket.com/stocks/news.php?code=VNRX&date=2024-03-25220851&utm_source=dlvr.it&utm_medium=tumblr
0 notes
Text
Colorectal Cancer Market to Explore Emerging Trends of Coming Years
The Colorectal Cancer Market is expected to grow from US$ 18,619.3 million in 2022 to US$ 24,078.5 million by 2028; it is expected to grow at a CAGR of 3.3% from 2022 to 2028.
The increasing prevalence of colorectal cancer and demand for advanced cancer diagnostics across the globe are driving the growth of the global colorectal cancer market. The government’s measures to control pharmaceutical prices are hampering the overall market growth. Rising market potential in developing economies is expected to provide lucrative opportunities for the global colorectal cancer market in the coming years. Furthermore, the growing number of product approvals and developments is likely to boost the market during the forecast period.
Colorectal cancer is also known as bowel, colon, or rectal cancer. This type of cancer is the second leading cause of death in women and the third leading cause of death in men. Colorectal cancer can be benign, noncancerous, or malignant. The symptoms of colon cancer patients include changes in bowel habits, diarrhea or constipation, and blood in stools that make it look black. Colorectal cancer can be treated with chemotherapy, radiotherapy, and surgery.
Get Sample PDF:
Based on modality, the global colorectal cancer market is segmented into diagnosis type, therapy type, and imaging type. The diagnosis type segment accounted for the largest share of the market in 2022. Further, it is anticipated to register a higher CAGR during the forecast period, owing to an increasing number of diagnostics tests done by patients. The diagnosis type segment is further categorized into immunochemistry, stool test, flexible sigmoidoscopy, colonoscopy, CEA test, and others. Leading companies offer a huge range of products; for instance, Roche offers robust tools to aid in colorectal cancer diagnostics; the portfolio of assays includes VENTANA MLH-1 (M1) Mouse Monoclonal Primary Antibody, VENTANA anti-MSH6 (SP93) Rabbit Monoclonal Antibody, and VENTANA CDX-2 (EPR2764Y).
Buy Now: https://www.theinsightpartners.com/buy/TIPRE00006881/
Impact of COVID-19 Pandemic on Global Colorectal Cancer Market
The COVID-19 pandemic has significantly affected the global healthcare system. To combat the spread of SAR-CoV-2, governments imposed stringent policies in 2020 and 2021 to prevent and reduce infection and mortality rates. Due to lockdown and travel restrictions, the global colorectal cancer market was adversely affected. This is mainly due to reduced CRC screening to prevent cancer patients from frequent travel to hospitals. Furthermore, hospitals postponed or canceled lengthy procedures to free up limited space for COVID-19 patients. The cancellation of surgeries to reduce exposure to COVID-19 in the hospital hampered the growth of the colorectal cancer market. However, the world is slowly recovering from the COVID-19 pandemic and has resumed rebuilding lives and economies. Therefore, with the easing of lockdowns worldwide and the resumption of elective procedures, the colorectal cancer market is expected to recover the loss over the coming years significantly.
Company Profiles
F. Hoffmann-La Roche AG
Epigenomics AG
Novigenix SA
Abbott Laboratories
Amgen Inc.
Volitionrx
EDP Biotech
Clinical Genomics Technologies Pvt Ltd
Bruker
Quest Diagnostics Incorporated
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: [email protected]
Phone: +1-646-491-9876
0 notes
Text
Colorectal Cancer Market Emerging with CAGR of 4.0% from 2021 to 2028
Colorectal cancer is also known as bowel cancer, colon cancer, or rectal cancer. This type of cancer is the second leading cause of death in women and third in men. Colorectal cancer may be benign, or non-cancerous, or malignant. The symptoms shown by the patients who have colon cancer include changes in bowel habits, diarrhea or constipation, blood in stools that make it look black. Colorectal cancer can be treated with chemotherapy, radiotherapy, and surgery. The growth of the Colorectal Cancer in healthcare market is attributed to the increasing prevalence of colorectal cancer, new product launches and benefits offered by generic drugs are boosting the market over the years. Also, the growing pharmaceutical industry emerging markets in developing countries are likely to have a positive impact on the growth of the market in the coming years.
The global colorectal cancer market, based on the modality, is segmented into diagnosis type, therapy type, and imaging type. In 2018, the diagnosis type segment held the largest market share of the colorectal cancer market. This segment is also projected to dominate the market in 2027 as it emphasizes the need for early recognition of neoplasms, or in the asymptomatic or pre-cancerous stage.
The market for colorectal cancer is expected to grow, owing to factors such as increasing prevalence of colorectal cancer, new product launches and benefits offered by generic drugs. Moreover, growing pharmaceutical industry in emerging economies is likely to have a positive impact on the growth of the market in the coming years.
The leading companies operating in the colorectal cancer market include Epigenomics AG, Novigenix SA, Clinical Genomics Technologies Pty Ltd., EDP Biotech Corporation, Volitionrx Limited, Abbott Laboratories, Amgen Inc., F. Hoffmann-La Roche AG, Bruker Corporation, Quest Diagnostics Incorporated, Natera, Inc., and Guardant Health, Inc among others. The market has observed various organic as well as inorganic developments during recent years in the colorectal cancer market. For instance, in October, 2019, Novigenix announced that Helsana, the leading health insurance provider in Switzerland has approved offering coverage for reimbursement for the Colox, a liquid biopsy test for early detection of colorectal cancer.
The Colorectal Cancer in healthcare market is expected to witness substantial growth post-pandemic. The COVID-19 has affected economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The COVID-19 crisis has overburdened public health systems in many countries and highlighted the strong need for sustainable investment in health systems. As the COVID-19 pandemic progresses, the healthcare industry is expected to see a drop in growth. The life sciences segment thrives due to increased demand for invitro diagnostic products and rising research and development activities worldwide. However, the medical technologies and imaging segment is witnessing drop in sales due to a smaller number of surgeries being carried out and delayed or prolonged equipment procurement. Additionally, virtual consultations by healthcare professionals are expected to become the mainstream care delivery model post-pandemic. With telehealth transforming care delivery, digital health will continue to thrive in coming years. In addition, disrupted clinical trials and the subsequent delay in drug launches is also expected to pave the way for entirely virtual trials in the future. New technologies such as mRNA is expected to emerge and shift the pharmaceutical industry and market is also expected to witness more vertical integration and joint ventures in coming years.
0 notes
Photo
VolitionRx: First commercial canine cancer blood test
4 notes
·
View notes
Photo
VolitionRx anuncia la presentación de declaraciones de registro AUSTIN, Texas, 7 de febrero de 2020 / PRNewswire / - VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") anunció hoy que ha presentado declaraciones de registro en el Formulario S-3 y el Formulario S-8, respectivamente, con el Comisión Nacional del Mercado de Valores.
0 notes
Text
Colorectal Cancer Market Overview, Merger and Acquisitions , Drivers, Restraints and Industry Forecast By 2027
The Global Colorectal Cancer Market is witnessing a remarkable growth owing to an increase in the demands for the products and a tremendous shift in consumer preferences. The high demand is concentrated in the European and North American countries. The report on Global Colorectal Cancer Market offers a comprehensive analysis of the recent advancements in the Colorectal Cancer industry and trends driving the growth of the market. The report offers the segmentation of the market on the basis of types, applications, and regions. The report is updated with the latest trends and economic scenario owing to the COVID-19 pandemic. The impact analysis of the pandemic is described in the report. A comprehensive analysis of the present and future impact of COVID-19 on the market, along with a post-COVID-19 scenario, is included in the report.
Get a sample of the report @https://www.reportsanddata.com/sample-enquiry-form/1596
Some of the key players operating in the Colorectal Cancer market include:
Abbott Laboratories
Amgen Inc.
Clinical Genomics
EDP Biotech
Epigenomics AG
Hoffmann-La Roche AG
Novigenix SA
Quest Diagnostics
Sanofi SA
Siemens Healthineers
VolitionRX
Segments covered in the report:
On the basis of regional analysis, the market is segmented into key geographical regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. According to the analysis, North America is expected to dominate the market with the highest market share. Asia-Pacific is anticipated to show a significant growth rate owing to rising development and population demands.
In situ Hybridization
Flow Cytometry
Next-generation Sequencing
Microarrays
Chemotherapy
Immunotherapy
Targeted therapy
Market segment by Procedure:
Biopsy
Mammography
Colostomy
Sigmoidoscopy
MRI
Request a discount on the report @https://www.reportsanddata.com/discount-enquiry-form/1596
Beneficial Aspects of the Report:
· Global and region forecast of the Colorectal Cancer market from 2020-2027
· In-depth analysis of market dynamics, industry outlook, market size based on types and applications
· Details of value chain analysis, supply and demand ratio, production and consumption patterns
· SWOT Analysis, Porter’s Five Forces Analysis, Feasibility Analysis, and Investment Return Analysis to provide a better understanding of the market and competitive players
· Detailed insights on competitive landscape and emerging market trends
Research Methodology:
The market report is formulated on the basis of data obtained through extensive primary and secondary research. The data is further validated and verified by industry experts, research analysts, and professionals. The report considers regional demand and supply ratio, investments, market dynamics, capacity, end-use industry trends, and consumer behavior to generate a forecast report. The data is collected from verified sources such as government policies, regulatory published materials, journals, trade magazines, and verified data sources. The report uses advanced analytical tools such as SWOT Analysis, Porter’s Five Forces Analysis, Feasibility Analysis, and Investment Return Analysis to provide an accurate insight into the market scenario and competitive landscape. This report provides beneficial information to companies and new players to make lucrative business decisions. The market estimates and forecast data have been thoroughly verified through exhaustive primary research.
To read more about the report –https://www.reportsanddata.com/report-detail/colorectal-cancer-market
Thank you for reading our report. Reports and Data provides customization of the report as per the needs of the clients. For further inquiry on customization, please connect with us and our team will ensure the report is tailored to fit your requirements.
Browse more reports:
Hot Melt Adhesives Market Size
Off Highway Vehicle Engine Market Share
1 note
·
View note
Link
VolitionRx Limited to Webcast Live at VirtualInvestorConferences.com February 4th
0 notes
Photo
NA Proactive news snapshot: BevCanna Enterprises Inc, VolitionRx Limited, Arizona Silver Exploration Inc, GlobeX Data LtdA glance at some of the day's highlights...https://bitprime.co/na-proactive-news-snapshot-bevcanna-enterprises-inc-volitionrx-limited-arizona-silver-exploration-inc-globex-data-ltd/?feed_id=6323&_unique_id=5d924c130d405
0 notes
Text
VolitionRx’s Nu.Q cancer-screening blood tests could replace colonoscopies, biopsies
VolitionRx (NYSEMKT:VNRX) - Belgium-based company’s Nu.Q test screens for colorectal and prostate cancers, and may have the potential to detect ovarian disease endometriosis...
0 notes
Text
Volitionrx Limited, a biomedical company that specializes in blood-based diagnostics, experienced a significant increase in its stock value over the past week and month. However, despite robust revenue growth, the company continues to face challenges. This article delves into Volitionrx Limitedns recent financial results and analyzes how these factors may impact the companyns future prospects.Impressive Revenue Growth:Volitionrx Limited reported a remarkable year-on-year revenue increase of 405.016% to $0.17 million in the most recent fiscal period. This surge indicates a strong demand for the companyns blood-based diagnostic solutions. Such exponential revenue growth demonstrates a positive market reception of Volitionrxns products and services.Losses and EPS:While revenue growth has been impressive, Volitionrx reported losses widening to $-0.11 during the same fiscal period. However, there was an improvement in earnings per share (EPS) when compared to the preceding quarter, with a decrease from $-0.14 to $-0.11 per share. Although the narrowing EPS loss is encouraging, the company still faces the cha https://csimarket.com/stocks/news.php?code=VNRX&date=2023-11-17163618&utm_source=dlvr.it&utm_medium=tumblr
0 notes
Text
Novel blood test detects early colorectal cancers, precancerous polyps
A blood test called Nu.Q detected 80% of stage 1 colorectal cancers and 66% of precancerous polyps in an asymptomatic screening study in Denmark, according to interim results reported by the developer, VolitionRx. The company plans on advancing the product through two further studies and hopes ...
from Google Alert - Gastroenterology http://ift.tt/2D6EP75
0 notes
Text
Setting A New 52 Week Low, VolitionRX Ltd (NYSE:VNRX) Closing At $1.57
Setting A New 52 Week Low, VolitionRX Ltd (NYSE:VNRX) Closing At $1.57
VolitionRX Ltd (NYSE:VNRX)
August 2nd, 2018
VolitionRX Ltd fell $0.16 Thursday, a 9.25% drop, closing at $1.57. As well as the drop in value, VolitionRX Ltd hit a new 52 week low of $1.44, breaking the previous low of $1.59 from earlier this month. VolitionRX Ltd swung 29.17% between low and high. Despite the drop in value, trading volumes were solid at 219% of normal which can indicate investor…
View On WordPress
0 notes
Text
Colorectal Cancer Market Size, Share, Growth, Analysis, Trend, and Forecast Research Report by 2027
Reports and Data has recently published a new research report on Global Colorectal Cancer Market that covers current development scenario and emerging trends of the market. The research report provides a comprehensive assessment of the market size, market share, revenue growth, and provides a futuristic perspective about the market trends, growth factors, facts, and industry validated market data. The report applies advanced statistical tools such as Porter’s Five Forces analysis and SWOT analysis to shed light on the competitive landscape of the global Colorectal Cancer market. The report covers all the critical and essential information relating to the global Colorectal Cancer market which helps the readers and clients gain a thorough understanding of the market.
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1596
The report initially offers market introduction, market overview, product scope, market opportunities, growth prospects, risks, limitations, and key drivers. The report also covers a comprehensive analysis of the competitive landscape with extensive profiling of the key competitors. It covers recent technological advancements, product developments, product launches, mergers and acquisitions, collaborations, joint ventures, and partnerships.
Key Companies in the market include:
Abbott Laboratories
Amgen Inc.
Clinical Genomics
EDP Biotech
Epigenomics AG
Hoffmann-La Roche AG
Novigenix SA
Quest Diagnostics
Sanofi SA
Siemens Healthineers
VolitionRX
Regional segmentation comprises of a current and forecast estimation of the market in the key geographical regions such as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report also covers the scope of individual applications and types in each region. The report also covers details about production and consumption patterns, technological developments, revenue growth, market size, market share, key trends and demands influencing market growth in the region, and robust presence of key players in the region.
Market segment analysis:
In situ Hybridization
Flow Cytometry
Next-generation Sequencing
Microarrays
Chemotherapy
Immunotherapy
Targeted therapy
Market segment by Procedure:
Biopsy
Mammography
Colostomy
Sigmoidoscopy
MRI
Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1596
Regional analysis further covers a country-wise analysis to offer insights into key trends and demands in each major country that might affect the growth of the market in the region.
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
U.S.
Canada
Mexico
Germany
U.K.
Italy
France
BENELUX
Rest of Europe
China
India
Japan
South Korea
Rest of APAC
Brazil
Rest of LATAM
Saudi Arabia
A.E.
South Africa
Rest of MEA
To know more about the report @ https://www.reportsanddata.com/report-detail/colorectal-cancer-market
Key Features of the Global Colorectal Cancer Market Report:
Comprehensive analysis of the key players operating in the market along with their SWOT analysis, their business profiles, business overview, market share, global position, and market value
Identification and analysis of significant trends and factors driving revenue growth of the market
Analysis of the competitive landscape along with strategic mergers, expansions, agreements, partnerships, joint ventures, acquisitions, and product launches
Assessment of each market segment along with their growth trends and market revenue contribution
Study of the key regions to pinpoint growth potential and study opportunities, threats, limitations, and risks
Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/1596
Thank you for reading our report. Customization of this report is available according to the client’s needs. Please get in touch with us to know more about the customization feature and our team will ensure the report is tailored as per your requirements.
Browse more reports:
Hot Melt Adhesives Market Size
Off Highway Vehicle Engine Market Share
0 notes
Text
VolitionRx to Attend Two Major Conferences in Asia
15, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will attend Asia Pacific Digestive Week ...
from Google Alert - Digestive http://ift.tt/2wfWTgj
0 notes
Text
Europe Colorectal Cancer Market to 2027: Market Research Subscriptions Platform, You Should Know About
Generic drugs are alternatives of branded drugs. The pharmacological effects of generic drugs are similar to their branded counterparts. Generic drugs are cost-effective as the manufacturers does not invest in the development and marketing a new drug. After the expiry of a drug patent, other manufacturers apply for FDA approval of a generic intended for its manufacturing and selling. Thus, the generic drugs are cheaper than their branded counterparts. The generic drug have exactly the same dosage, effects, side effects, route of administration, risks, safety, and strength as that of the original branded drugs. Generic drugs are important in oncology due to the fact that some of the anticancer drugs are only offered as generics.
Patients are likely seen to abandon branded prescriptions which are majorly associated with their higher co-pays. Among developing countries such as India, where the paying capacity is relatively low, generic drugs for cancer treatment acts as a boon for both the manufacturers as well as patients due to its affordability and efficacy. For instance, in June 2016, Hetero launched a Biosimilar 'Bevacizumab' for the treatment of metastatic colorectal cancer under the brand name “Cizumab”. One of the most striking benefit of using generic drugs is the cost that is up to 85% less than that of the branded drugs.
The rise of the is driven by factors such as the increasing prevalence of colorectal cancer, and benefits offered by generic drugs that are boosting the market over the years. But, pricing pressure on drug manufacturers is likely to hinder the growth of the market in the future years.
Register for a free trial today and gain instant access to our market research reports at
https://www.businessmarketinsights.com/TIPRE00008334/request-trial
In 2019, the Germany accounted for the largest market share in Europe colorectal cancer market, and it is also expected to grow at a faster pace over the forecast period. The market for colorectal cancer in the country is expected to grow due to the rising development in the field of cancer. Across the country, there are various biopharmaceutical and pharmaceutical companies. Various multinational companies are conducting market consolidation strategies to expand the oncology segment. Hence, considering the mentioned factors, the colorectal cancer market is expected to grow at a significant pace in the US during the forecast period.
EUROPE COLORECTAL CANCER – MARKET SEGMENTATION
By Modality
Immunohistochemistry
Stool Test
Flexible Sigmoidoscopy
Colonoscopy
CEA Test
Others
Chemotherapy
Alkylating Agent
Antimetabolites
Others
Immunotherapy
Panitumumab
Cetuximab
Bevacizumab
Others
Chemoprotectant
Others
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Others
By End User
Hospitals
Diagnostic and Research Laboratories
By Geography
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Company Profiles
Epigenomics AG
Novigenix SA
Clinical Genomics Technologies Pty Ltd.
EDP Biotech Corporation
Volitionrx Limited
Abbott Laboratories
Amgen Inc.
F. Hoffmann-La Roche AG
Bruker Corporation
Quest Diagnostics Incorporated
Natera, Inc.
Guardant Health, Inc.
Business Market Insights provides affordable subscription with pay as per requirement at https://www.businessmarketinsights.com/TIPRE00008334/checkout/basic/single/monthly
(30-day subscription plans prove to be very cost-effective with no compromise on the quality of reports)
Benefits with Business Market Insights
ü One Stop Platform to All the Market Insight Needs
ü Avoid Long Purchase Procedures
ü Fast and Easy Access
ü Cloud-Based Platform
ü News Updates
ü Ask the Analyst Support
ü Pay Monthly Subscription and Access All You Want
ü No Compulsion for Yearly Subscription
ü Reports Read or Download Access
ü Monthly New Reports Added
ü Affordable Product, Pay as Per Requirement
About Business Market Insights
Based in New York, Business Market Insights is a one-stop destination for in-depth market research reports from various industries including Technology, Media & Telecommunications, Semiconductor & Electronics, Aerospace & Defense, Automotive & Transportation, Biotechnology, Healthcare IT, Manufacturing & Construction, Medical Device, and Chemicals & Materials. The clients include corporate and academic professionals, consulting, research firms, PEVC firms, and professional services firms.
For Subscription contact
Business Market Insights
Phone : +442081254005
E-Mail : [email protected]
0 notes
Last Seen Blogs
out-action-bit-once
Untitled
gapsbetweenlovers
laur
i-love-neko
ねこだいすき
flyshitiwant
Fly Shit I Want
kiriani
kiriani